Cryonics Revival Scenarios & Potential Roadmaps & Hypotheses

Published October 14, 2026.

Two UCLA-led studies are offering a more detailed picture of why immune-checkpoint therapy usually struggles against glioblastoma — and what a productive immune response may look like in the minority of patients who benefit. One study reports findings from a phase 2 trial in recurrent glioblastoma; the other describes a preclinical tumor model designed to better reproduce the human disease.

A phase 2 window-of-opportunity trial

The clinical study enrolled 63 people whose glioblastoma had returned and who were already scheduled for surgery. Before the operation, participants received nivolumab plus ipilimumab, nivolumab alone or placebo. This design allowed investigators to examine the resected tumors and compare how the treatments changed the immune environment.

According to UCLA’s October 13 report, median overall survival was about 13.5 months in the combination group and roughly nine months with nivolumab alone. Five patients — approximately 15% of those receiving the combination — were described as long-term survivors, while no long-term responders were observed with nivolumab alone. The combination also produced greater T-cell infiltration and stronger interferon-related gene activity inside tumors.

Higher tumor T-cell density was independently associated with longer survival, making it a candidate biomarker for future study. Early inflammatory changes in blood and on MRI were also associated with better outcomes in some patients.

A model of an “immune-cold” brain tumor

The second study used Mosaic Analysis with Dual-Recombinase (MADR) technology to create a preclinical glioblastoma model carrying patient-relevant alterations, including EGFRvIII and loss of the tumor suppressors PTEN and CDKN2A. The resulting tumors grew diffusely, contained many myeloid cells but few cancer-fighting T cells, and resisted immune-checkpoint blockade — characteristics that more closely resemble human glioblastoma than some commonly used models.

The model also showed intrinsic resistance to T-cell killing and signs of T-cell exhaustion. Researchers plan to use it to test strategies intended to open the tumor to immune attack, including brain-penetrant EGFR inhibitors and next-generation mRNA vaccines.

Important limitations

The clinical trial was a small phase 2 study in recurrent disease. Its survival figures should not be treated as definitive proof that the combination prolongs life, and the findings require confirmation in larger, appropriately powered trials. The immune markers are promising hypotheses, not yet validated tests for choosing treatment. The MADR results are preclinical and do not establish benefit in patients.

Sources: UCLA Health, October 13, 2026; the linked peer-reviewed studies in Nature Communications and Cancer Research.